Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete remission (CR1). To compare this association with that for patients in second complete remission (CR2) and to examine the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Walter, Roland B., Buckley, Sarah A., Pagel, John M., Wood, Brent L., Storer, Barry E., Sandmaier, Brenda M., Fang, Min, Gyurkocza, Boglarka, Delaney, Colleen, Radich, Jerald P., Estey, Elihu H., Appelbaum, Frederick R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2013
Gaiak:
Transplantation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3765060/
https://ncbi.nlm.nih.gov/pubmed/23847197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-506725
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak